Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness

21 Apr 2023

Abstract excerpt

Background aims Therapeutic disruption of immune checkpoints has significantly advanced the armamentarium of approaches for treating cancer. The prominent role of the programmed death-1 (PD-1)/programmed death ligand-1 axis for downregulating T cell function offers a tractable strategy for enhancing the disease-modifying impact of CAR-T cell therapy. Methods To address checkpoint interference, primary human T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37086241
DOI: 10.1016/j.jcyt.2023.03.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitnessPMID 37086241Read ↗

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome.Semantic proximity Read ↗

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editingSemantic proximity Read ↗

Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapySemantic proximity Read ↗

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challengesSemantic proximity Read ↗

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.Semantic proximity Read ↗

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphomaSemantic proximity Read ↗

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancersSemantic proximity Read ↗

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read ↗

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapySemantic proximity Read ↗

Comprehensive genome editing confers ‘off-the-shelf’ CAR-T cells superior efficacy against solid tumorsSemantic proximity Read ↗

CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapySemantic proximity Read ↗

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.